AL 2846

Drug Profile

AL 2846

Alternative Names: AL-2846

Latest Information Update: 22 Nov 2016

Price : $50

At a glance

  • Originator Advenchen Laboratories
  • Developer Advenchen Laboratories; Chia Tai Tianqing Pharmaceutical Group
  • Class Antineoplastics; Small molecules
  • Mechanism of Action RON protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cancer

Most Recent Events

  • 09 Nov 2016 Phase-I clinical trials in Cancer in China (PO) (NCT02779699)
  • 03 Jun 2016 Jiangsu Chia-tai Tianqing Pharmaceutical plans a phase I trial for Cancer in China (NCT02779699)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top